It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

pharmaceuticals

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Japan’s AnGes continues surge as coronavirus vaccine candidate moves closer to human trials

Business / Corporate / Financial Markets May 26, 2020

Japan’s AnGes continues surge as coronavirus vaccine candidate moves closer to human trials

The progress of its drug development has led to wild swings in the stock, with shares falling more than 50 percent in two trading sessions earlier this month.

Gilead’s remdesivir mainly helped healthier COVID-19 patients

World / Science & Health May 23, 2020

Gilead’s remdesivir mainly helped healthier COVID-19 patients

Gilead Sciences Inc.’s remdesivir, the first medicine cleared for the treatment of COVID-19, mainly benefited healthier patients who weren’t dependent on ventilators or heart-lung bypass machines, according to published results of the study used to get the medicine on the market. The drug helped patients ...

Fujifilm plans to make flu drug Avigan available for 2 million people by March 2021

Business May 22, 2020

Fujifilm plans to make flu drug Avigan available for 2 million people by March 2021

Fujifilm Holdings Corp. said Friday it is on course to supply the flu drug Avigan for 2 million COVID-19 patients by next March, meeting a target set by the government to ramp up production of the potential but yet unapproved coronavirus treatment. "We plan to ...

Japan to subsidize mass production of eventual coronavirus vaccine

National / Science & Health May 22, 2020

Japan to subsidize mass production of eventual coronavirus vaccine

More than 110 coronavirus vaccine development projects are underway worldwide, with some in the clinical testing phase, according to a WHO list.

Fukuoka startup to tap RNA tech for inhalable COVID-19 treatment

Business May 21, 2020

Fukuoka startup to tap RNA tech for inhalable COVID-19 treatment

A biotechnology startup in Fukuoka Prefecture is partnering with local authorities to develop a drug to treat COVID-19 using its RNA technology. Bonac Corp., based in Kurume, says only two other companies in the world are trying to develop a nucleic acid medicine for the ...

No pause in coronavirus trial for Avigan, Japan's lead researcher says

Business May 21, 2020

No pause in coronavirus trial for Avigan, Japan's lead researcher says

by Lisa Du and Grace Huang

The lead researcher in the coronavirus trial for flu drug Avigan says it’s too early to make a call on whether it works and shrugged off negative reports about the interim results, saying patients are still being enrolled. The final results of the trial for ...

Drug Avigan that was pushed by Abe falls short in COVID-19 trials

Science & Health May 20, 2020

Drug Avigan that was pushed by Abe falls short in COVID-19 trials

The lack of results have raised doubts about its approval by the end of this month, as sought by the government.

Vaccine developers need to take their time

Commentary / World May 19, 2020

Vaccine developers need to take their time

by Max Nisen

Positive study results have arrived quickly, but the next steps will be slower.

Trump says he’s taking anti-malaria drug that led to FDA warning

World May 19, 2020

Trump says he’s taking anti-malaria drug that led to FDA warning

Trump is a self-admitted germophobe, telling reporters he was wary of shaking hands even before the coronavirus pandemic.

France says ‘unacceptable’ for U.S. to get Sanofi vaccine first

World / Science & Health May 14, 2020

France says ‘unacceptable’ for U.S. to get Sanofi vaccine first

Giving the U.S. priority access to a Sanofi vaccine against the new coronavirus would be "unacceptable,” a French government minister said. "For us, it would be unacceptable that there be privileged access for this or that country on a pretext that would be a financial ...

Takeda says trial based on blood of recovered virus patients could start in July

Business May 14, 2020

Takeda says trial based on blood of recovered virus patients could start in July

Fighting disease with blood from survivors is an ancient strategy that has not been well tested for the novel coronavirus.

Japan's health insurance to cover ¥167 million gene therapy drug

National / Science & Health May 13, 2020

Japan's health insurance to cover ¥167 million gene therapy drug

Considered the world's most expensive medicine, relatively few cases are expected to require the one-time dosage of drug to treat spinal muscular atrophy.

« 1 … 33 34 35 … 42 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times